Search

Your search keyword '"Hoffmann, Markus"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Hoffmann, Markus" Remove constraint Author: "Hoffmann, Markus" Publisher springer science and business media llc Remove constraint Publisher: springer science and business media llc
72 results on '"Hoffmann, Markus"'

Search Results

1. Phosphatidylserine-exposing extracellular vesicles in body fluids are an innate defence against apoptotic mimicry viral pathogens

3. Glucose-stimulated insulin secretion depends on FFA1 and Gq in neonatal mouse islets

6. Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5

8. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

10. Spanning Fermi arcs in a two-dimensional magnet

12. BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

13. Peptidomimetic inhibitors of TMPRSS2 block SARS-CoV-2 infection in cell culture

14. Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2

16. MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination

18. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses

20. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

21. Spike residue 403 affects binding of coronavirus spikes to human ACE2

22. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

23. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance

24. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination

25. Quantum spin mixing in Dirac materials

26. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

28. Patients with COVID-19: in the dark-NETs of neutrophils

29. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection

34. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

35. Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2

36. Author Correction: A MHz-repetition-rate hard X-ray free-electron laser driven by a superconducting linear accelerator

37. LY6E impairs coronavirus fusion and confers immune control of viral disease

39. A MHz-repetition-rate hard X-ray free-electron laser driven by a superconducting linear accelerator

40. Therapeutic ACPA inhibits NET formation: a potential therapy for neutrophil-mediated inflammatory diseases

41. IgA subclasses have different effector functions associated with distinct glycosylation profiles

42. Quantum supremacy using a programmable superconducting processor

43. To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps

45. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway

50. Blood-borne phagocytes internalize urate microaggregates and prevent intravascular NETosis by urate crystals

Catalog

Books, media, physical & digital resources